- Home
- DVAX vs TRVI Comparison
DVAX vs TRVI Comparison
Compare DVAX & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVAX
- TRVI
- Stock Information
- Founded
- DVAX 1996
- TRVI 2011
- Country
- DVAX United States
- TRVI United States
- Employees
- DVAX N/A
- TRVI N/A
- Industry
- DVAX Biotechnology: Pharmaceutical Preparations
- TRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DVAX Health Care
- TRVI Health Care
- Exchange
- DVAX Nasdaq
- TRVI Nasdaq
- Market Cap
- DVAX 1.2B
- TRVI 1.4B
- IPO Year
- DVAX 2004
- TRVI 2019
- Fundamental
- Price
- DVAX $11.21
- TRVI $11.55
- Analyst Decision
- DVAX Buy
- TRVI Strong Buy
- Analyst Count
- DVAX 4
- TRVI 10
- Target Price
- DVAX $26.50
- TRVI $21.05
- AVG Volume (30 Days)
- DVAX 1.7M
- TRVI 1.5M
- Earning Date
- DVAX 11-05-2025
- TRVI 11-13-2025
- Dividend Yield
- DVAX N/A
- TRVI N/A
- EPS Growth
- DVAX N/A
- TRVI N/A
- EPS
- DVAX N/A
- TRVI N/A
- Revenue
- DVAX $330,514,000.00
- TRVI N/A
- Revenue This Year
- DVAX $23.23
- TRVI N/A
- Revenue Next Year
- DVAX $16.57
- TRVI N/A
- P/E Ratio
- DVAX N/A
- TRVI N/A
- Revenue Growth
- DVAX 26.73
- TRVI N/A
- 52 Week Low
- DVAX $9.20
- TRVI $2.36
- 52 Week High
- DVAX $14.63
- TRVI $12.30
- Technical
- Relative Strength Index (RSI)
- DVAX 64.07
- TRVI 58.67
- Support Level
- DVAX $10.97
- TRVI $11.15
- Resistance Level
- DVAX $11.43
- TRVI $12.14
- Average True Range (ATR)
- DVAX 0.36
- TRVI 0.68
- MACD
- DVAX 0.07
- TRVI -0.03
- Stochastic Oscillator
- DVAX 86.42
- TRVI 59.86
About DVAX Dynavax Technologies Corporation
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.